Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Squamous cell carcinoma of the bladder does not promote high-risk HPV

31 Jul 2020

High-risk human papilloma virus (HPV) infection occurs rarely in patients with squamous cell carcinoma (SCC) of the bladder, despite having an aggressive histologic subtype, a study has found.

Researchers looked at 207 patients with SCCs of the bladder (mean age at the time of diagnosis, 66 years; 43.5 percent female). Of these patients, 133 (64.3 percent) had a smoking history and 83 (40.1 percent) had medical conditions leading to chronic bladder irritation such as stones, indwelling catheters, and chronic urinary tract infection. None had a history of Schistosoma infection.

The majority (75 percent) of patients presented with a higher-stage (>pT2) disease at the time of cystectomy. Mean tumour size was 5.6 cm, and 36 (17 percent) patients had lymph node positive disease.

Of the 204 patients included in the p16 IHC and high-risk HPV ISH analyses, 52 (25 percent) exhibited diffuse p16 expression and only a single patient (0.5 percent) had high-risk HPV.

Over a mean follow-up of 4.6 years, 76 patients (36.7 percent) had disease recurrence and 90 (43.5 percent) died from SCC of the bladder. The mean overall survival was 9.52 years, time-to cancer-specific mortality was 17.0 years, and recurrence-free survival was 8.70 years.

Significant predictors of cancer-specific mortality were tumour size (hazard ratio [HR], 1.23), number of lymph nodes removed (HR, 0.98), number of positive lymph nodes (HR, 1.28), and perineural invasion (HR, 2.19).

In genital and oral cancers, high-risk HPV has been linked to the overexpression of the p16 protein, the researchers noted. However, this does not appear to be the case for bladder cancer, specifically SCC. This discrepancy may be explained by cross contamination of close regional HPV-driven SCCs in previous studies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.